CLINUVEL Communiqué III
Since News Communiqué II on 31 March 2022, the Company has reported...
Read More
Jeffries Healthcare Conference June 2022
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the Jeffries Healthcare...
Read More
H.C. Wainwright Global Investment Conference 2022
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...
Read More
Strategic Update IV
CLINUVEL today announced its fourth Strategic Update, focused on the Group’s view...
Read More
ACTH Manufacturing Update
CLINUVEL is progressing scaled manufacturing of adrenocorticotropic hormone (ACTH) under current Good...
Read More
CLINUVEL’S GROWTH AND EXPANSION - H.C. Wainwright Bioconnect Conference 2022
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...
Read More
Progress of CLINUVEL’s DNA Repair Program
CLINUVEL PHARMACEUTICALS LTD today announced that two xeroderma pigmentosum (XP) patients have...
Read More
Chair's Letter to Shareholders
On behalf of the Board, thank you to those shareholders who chose...
Read More
CLINUVEL Kommuniqué VI
Der letzte Monat war eine tragische Lektion in Bezug auf die Herausforderungen...
Read More
SCENESSE® as Vitiligo Monotherapy
CLINUVEL’s drug SCENESSE® (afamelanotide 16mg) will be evaluated as a monotherapy in...
Read More